Log in

Gossamer Bio Stock Forecast, Price & News

+0.04 (+0.45 %)
(As of 11/27/2020 12:00 AM ET)
Today's Range
Now: $8.98
50-Day Range
MA: $9.51
52-Week Range
Now: $8.98
Volume239,067 shs
Average Volume603,161 shs
Market Capitalization$681.83 million
P/E RatioN/A
Dividend YieldN/A
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2, which is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma; in Phase II clinical trial to treat patients with chronic rhinosinusitis both with and without nasal polyps; and in translational Phase 2 clinical trial in patients with chronic spontaneous urticarial. The company is also developing GB002, an orally inhaled, small molecule, selective platelet-derived growth factor receptor kinase inhibitor in Phase Ib clinical trial for the treatment of pulmonary arterial hypertension; GB004, a novel, gut-targeted, oral small molecule in Phase Ib clinical trial for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; and GB1275, an oral, small molecule, CD11b modulator in Phase 1/2 clinical trial for the treatment of selected solid tumor types. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and certain backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was founded in 2015 and is headquartered in San Diego, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 4.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.19 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:GOSS



Sales & Book Value

Annual SalesN/A
Book Value$5.34 per share


Net Income$-180,310,000.00


Market Cap$681.83 million
Next Earnings Date3/23/2021 (Estimated)
OptionableNot Optionable
+0.04 (+0.45 %)
(As of 11/27/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GOSS News and Ratings via Email

Sign-up to receive the latest news and ratings for GOSS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Gossamer Bio (NASDAQ:GOSS) Frequently Asked Questions

How has Gossamer Bio's stock price been impacted by COVID-19 (Coronavirus)?

Gossamer Bio's stock was trading at $10.59 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, GOSS shares have decreased by 15.2% and is now trading at $8.98.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Gossamer Bio?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gossamer Bio in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Gossamer Bio
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Gossamer Bio?

Wall Street analysts have given Gossamer Bio a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Gossamer Bio wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Gossamer Bio's next earnings date?

Gossamer Bio is scheduled to release its next quarterly earnings announcement on Tuesday, March 23rd 2021.
View our earnings forecast for Gossamer Bio

How were Gossamer Bio's earnings last quarter?

Gossamer Bio, Inc. (NASDAQ:GOSS) released its earnings results on Sunday, November, 15th. The company reported ($0.80) earnings per share for the quarter, beating the consensus estimate of ($0.85) by $0.05.
View Gossamer Bio's earnings history

What price target have analysts set for GOSS?

6 brokerages have issued 1 year price objectives for Gossamer Bio's stock. Their forecasts range from $15.00 to $32.00. On average, they anticipate Gossamer Bio's share price to reach $22.83 in the next twelve months. This suggests a possible upside of 154.3% from the stock's current price.
View analysts' price targets for Gossamer Bio

Who are some of Gossamer Bio's key competitors?

What other stocks do shareholders of Gossamer Bio own?

Who are Gossamer Bio's key executives?

Gossamer Bio's management team includes the following people:
  • Mr. Faheem Hasnain, Co-Founder & Chairman (Age 62, Pay $926.36k)
  • Dr. Sheila K. Gujrathi M.D., Co-Founder, Pres, CEO & Director (Age 50, Pay $830k)
  • Mr. Bryan Giraudo, Chief Financial Officer (Age 44, Pay $580.8k)
  • Dr. Luisa Salter-Cid Ph.D., Chief Scientific Officer (Age 61, Pay $548.69k)
  • Mr. Christian Waage, Exec. VP, Gen. Counsel & Sec. (Age 53)
  • Ms. Deanna Weber, VP of HR
  • Dr. Richard Aranda, Sr. VP of Clinical Devel.

When did Gossamer Bio IPO?

(GOSS) raised $230 million in an initial public offering on Friday, February 8th 2019. The company issued 14,400,000 shares at a price of $16.00 per share. BofA Merrill Lynch, Leerink Partners, Barclays and Evercore ISI served as the underwriters for the IPO.

What is Gossamer Bio's stock symbol?

Gossamer Bio trades on the NASDAQ under the ticker symbol "GOSS."

Who are Gossamer Bio's major shareholders?

Gossamer Bio's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.12%), State Street Corp (2.84%), Federated Hermes Inc. (2.66%), Victory Capital Management Inc. (2.33%), Jennison Associates LLC (1.95%) and Charles Schwab Investment Management Inc. (0.44%). Company insiders that own Gossamer Bio stock include Bryan Giraudo, Faheem Hasnain, Fund V Gp LP Omega, Jakob Dupont, Luisa Salter-Cid, Russell J Cox and Waage Christian.
View institutional ownership trends for Gossamer Bio

Which major investors are selling Gossamer Bio stock?

GOSS stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, SG Americas Securities LLC, Wells Fargo & Company MN, Boothbay Fund Management LLC, Alps Advisors Inc., Alps Advisors Inc., and Virtus ETF Advisers LLC.
View insider buying and selling activity for Gossamer Bio

Which major investors are buying Gossamer Bio stock?

GOSS stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Victory Capital Management Inc., State Street Corp, Federated Hermes Inc., GSA Capital Partners LLP, Arrowstreet Capital Limited Partnership, California Public Employees Retirement System, and Public Employees Retirement System of Ohio. Company insiders that have bought Gossamer Bio stock in the last two years include Bryan Giraudo, Faheem Hasnain, Russell J Cox, and Waage Christian.
View insider buying and selling activity for Gossamer Bio

How do I buy shares of Gossamer Bio?

Shares of GOSS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Gossamer Bio's stock price today?

One share of GOSS stock can currently be purchased for approximately $8.98.

How big of a company is Gossamer Bio?

Gossamer Bio has a market capitalization of $681.83 million. The company earns $-180,310,000.00 in net income (profit) each year or ($3.29) on an earnings per share basis. Gossamer Bio employs 171 workers across the globe.

What is Gossamer Bio's official website?

The official website for Gossamer Bio is www.gossamerbio.com.

How can I contact Gossamer Bio?

Gossamer Bio's mailing address is 3013 SCIENCE PARK, SAN DIEGO CA, 92121. The company can be reached via phone at 858-922-0718.

This page was last updated on 11/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.